Report : Asia Pacific Organoids Market Forecast to 2030 – Regional Analysis – by Organ Type (Intestine, Liver, Stomach, Pancreas, Lung, Brain, Kidney, and Others), Application (Development of Biology Disease, Pathology of infectious Disease, Regenerative Medicines, Drug Discovery and Personalized Medicine, Drug Toxicity and Efficacy Testing, and Others), Source (Pluripotent Stem Cell and Organ Specific Adult Stem Cell), and Type (Instruments, Consumables, and Services)
At 23.7% CAGR, the Asia Pacific Organoids Market is speculated to be worth US$ 1,866.32 million by 2030, says Business Market Insights
According to Business Market Insights research, the Asia Pacific Organoids market was valued at US$ 341.24 million in 2022 and is expected to reach US$ 1,866.32 million by 2030, registering a CAGR of 23.7% from 2022 to 2030. Growing adoption of personalized drugs and rising focus on developing alternatives for animal testing models are the critical factors attributed to the Asia Pacific Organoids market expansion.
Personalized medicine, also known as precision medicine, is a medical model that practices procedures or drugs tailored to the individual patient based on the projected response or risk of disease. According to a study published by Personalized Medicine Coalition (PMC), personalized medicines accounted for only 5% of the new FDA-approved molecular entities in 2005, whereas they accounted for more than 25% in 2016. Additionally, 42% of all compounds and 73% of oncology compounds in the pipeline have the potential to be personalized medicines. Moreover, biopharmaceutical companies nearly doubled their R&D investment in personalized drugs over the past five years, which is likely to increase by 33% in the next five years. Biopharmaceutical researchers also predict a 69% increase in the development of personalized medicines over the coming five years.
The implementation of organoids to create personalized drug therapies provides exciting opportunities for improving patient care. In addition, pharmacists play an essential role in increasing the demand for personalized medicines as they proactively educate and create awareness about precision medicine. Recent research has highlighted that more than 50% of consumers are interested in purchasing customized products or services. This demand has persuaded pharmaceutical research to develop more tailored treatments to make medicines safer and more effective.
Personalized cancer medicine is an approach to tailoring effective therapeutic strategies for each patient according to a tumor’s genomic characterization. There is an increasing demand for research in personalized tumor modeling to confirm the functional aspects of genomic drug response predictions in the preclinical setting. Numerous studies have highlighted the application of tumor organoids in personalized cancer medicine in terms of gene–drug association treatment, identification of new therapies, and prediction of patient outcomes.
Personalized cancer therapy applies specific treatments to each patient. Using personalized tumor models with similar characteristics to the original tumors may result in accurate predictions of drug responses in patients. Tumor organoid models have several advantages, such as conserving the molecular and cellular composition of the original tumor over pre-existing models. These advantages highlight the tremendous potential of tumor organoids in personalized cancer therapy, particularly in preclinical drug screening and predicting patient responses to selected treatment regimens.
On the contrary, issues related to incorporation of organoids into existing workflows hampers the Asia Pacific organoids market.
Based on organ type, the Asia Pacific organoids market is segmented into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held 23.1% share of Asia Pacific organoids market in 2022, amassing US$ 78.97 million. It is projected to garner US$ 424.02 million by 2030 to expand at 23.4% CAGR during 2022–2030.
Based on type, the Asia Pacific organoids market is segmented into instruments, consumables, and services. The consumables segment held 57.5% share of Asia Pacific organoids market in 2022, amassing US$ 196.05 million. It is projected to garner US$ 1,136.42 million by 2030 to expand at 24.6% CAGR during 2022–2030.
Based on application, the Asia Pacific organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held 29.6% share of Asia Pacific organoids market in 2022, amassing US$ 100.84 million. It is projected to garner US$ 577.32 million by 2030 to expand at 24.4% CAGR during 2022–2030.
Based on source, the Asia Pacific organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cell. The pluripotent stem cells segment held 72.2% share of Asia Pacific organoids market in 2022, amassing US$ 246.54 million. It is projected to garner US$ 1,391.07 million by 2030 to expand at 24.1% CAGR during 2022–2030.
Based on country, the Asia Pacific organoids market has been categorized into the Japan, China, India, South Korea, Australia, and the Rest of Asia Pacific. Our regional analysis states that Japan captured 36.0% share of Asia Pacific organoids market in 2022. It was assessed at US$ 122.86 million in 2022 and is likely to hit US$ 643.99 million by 2030, exhibiting a CAGR of 23.0% during 2022–2030.
Key players operating in the Asia Pacific organoids market are Cellesce, Corning Inc, InSphero, Merck KGaA, STEMCELL Technologies Inc, and Thermo Fisher Scientific Inc, among others.
- In Aug 2021, InSphero AG announced that it is making its proprietary, patented 96- and 384-microwell plates available to researchers, enabling them to access the same plate technology used in the company’s flagship, assay-ready 3D InSight Human Liver Microtissues. The plates, engineered specifically for 3D cultures of spheroids and organoids, are available via InSphero’s online R&D Solutions Store.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com